Investigating factors influencing cancer risk in people with Lynch syndrome
Official title: The GEOLynch Cohort Study: Genetic, Environmental and Other Factors That Influence Tumour Risk Among Persons With Lynch Syndrome
Run by Wageningen University · NCT03303833 · Data updated 2026-11-12
This study is trying to find out how lifestyle, diet, and genetics affect cancer risk in people with Lynch syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Wageningen University Academic / other |
| Locations | 1 site (Wageningen) |
| Status | Recruiting |
| Started | July 1, 2006 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | October 6, 2017 |
| Trial ID | NCT03303833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 18 to 80 with a confirmed mutation in genes associated with Lynch syndrome.
✕Probably not a fit
Patients with additional hereditary cancer syndromes, chronic inflammatory bowel disease, or severe mental conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The GEOLynch cohort study focuses on individuals with Lynch syndrome, a genetic condition that increases the risk of certain cancers. Participants are asked to complete questionnaires regarding their lifestyle, diet, and health, and provide biological samples for genetic analysis. The study aims to understand how genetic, environmental, and lifestyle factors contribute to tumor risk in this population. It has been ongoing since 2006, with both new and previous participants contributing data and samples for future research.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and prevention strategies for individuals with Lynch syndrome.
How similar studies have gone: Other studies have shown success in understanding cancer risks in hereditary syndromes, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene. * Aged between 18 and 80 years at inclusion. Exclusion Criteria: * Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP) * (Chronic) Inflammatory bowel disease * Non-Dutch speaking * Dementia or another mental condition that makes it impossible to fill out questionnaires * Terminally ill persons
Where it's running
-
Wageningen University
Wageningen, Netherlands Recruiting
Study contacts
- Principal investigator: Ellen Kampman, PhD — Wageningen University
- Study coordinator: Fränzel van Duijnhoven, PhD
- Email: franzel.vanduijnhoven@wur.nl
- Phone: +31 317 485 375
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
High-sensitivity blood test to detect and monitor multiple cancers
This study will test a high-sensitivity blood test that looks for tumor DNA to detect and follow several common cancers in adults with those cancers or people having routine health screenings.
-
Evaluating HTL0039732 for Advanced Solid Tumours
This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.
-
Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples
This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer
A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.